• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics tops Q4 EPS estimates, misses sales expectations

March 14, 2018 By Sarah Faulkner

SenseonicsShares in Senseonics (NYSE:SENS) closed down -3% yesterday after the medical device maker met earnings expectations on Wall Street with its fourth quarter and full-year financial results, but narrowly missed sales estimates.

The Germantown, Md.-based company posted a net loss of -$16.3 million, or -12¢ per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line loss of -64.6% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -12¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $2.97 million.

For the full year, Senseonics posted a net loss of -$59.1 million, down -34.6% from 2016, on sales of $6.4 million – up from $0.3 million compared to the year before.

“We are pleased with our fourth quarter results and accomplishments through 2017 as well as the upcoming opportunity to present our strong clinical data to the FDA advisory panel, which is a milestone in building the Eversense franchise,” president & CEO Tim Goodnow said in prepared remarks. “We expect that the upcoming year will be transformational as we prepare to introduce Eversense to the U.S. market,  continue working with our distribution partners to expand our presence in Europe and continue with the launch of Eversense XL in Europe.”

Senseonics said it expects to post sales in the range of $18 million – $20 million in 2018.

SENS shares were trading at $3.07 apiece yesterday when the market closed, down -2.9%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS